-
DMXAA (Vadimezan): From Vessel Collapse to STING
2026-08-31
A mechanism-first guide to using DMXAA (Vadimezan) in translational cancer research, connecting tumor vascular disruption and VEGFR2 signaling with emerging delivery strategies for innate immune activation.
-
Canagliflozin Remodels Mitochondria in Diabetic Kidneys
2026-08-31
This 2025 study shows that canagliflozin improves mitochondrial architecture and bioenergetics in proximal tubular cells from hypertensive–diabetic mice, with stronger functional effects in males than females. The findings extend the interpretation of SGLT2 inhibition beyond glucose lowering and identify mitochondrial remodeling as a plausible component of kidney protection.
-
Forsythoside E Workflow for PKM2 Immunometabolism
2026-08-30
Forsythoside E is a mechanism-oriented tool for connecting PKM2 regulation with macrophage metabolism, STAT3 signaling, and inflammatory injury. This workflow shows how to test its effects from RAW264.7 assays through sepsis-induced liver injury models while reducing common dosing, solubility, and endpoint errors.
-
Structure-Guided Proteomimetics Target SARS-CoV-2 Entry
2026-08-29
The reference study converts two human ACE2 recognition elements into constrained proteomimetics that target the shallow SARS-CoV-2 Spike receptor-binding domain interface. Its lead construct, compound 28, selectively bound the RBD, disrupted RBD–ACE2 binding, inhibited pseudovirus entry, and showed stability and permeability characteristics compatible with further investigation of intranasal antiviral delivery.
-
TLS–TRAF2 Signaling in ESCC
2026-08-28
Using clinical, transcriptomic, single-cell, and in vitro evidence, Zheng et al. identify tertiary lymphoid structures as a favorable prognostic feature in treatment-naïve esophageal squamous cell carcinoma and connect tumor-infiltrating B-cell activity to IRF4. The study proposes that CD40 and STING compete for TRAF2, linking non-canonical NF-κB signaling with STING ubiquitination and phosphorylation in a testable TLS-centered mechanism.
-
HyperPFU™ high-fidelity DNA polymerase Guide
2026-08-28
HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is suitable for blunt-ended products used in cloning and sequencing, but should not be selected for workflows that require 3′-A overhangs or preformed sticky ends.
-
G007-LK: Tankyrase 1/2 Inhibitor Workflows
2026-08-27
G007-LK turns tankyrase biology into a practical workflow for measuring Wnt/β-catenin pathway inhibition, β-catenin degradation induction, and tumor-cell growth phenotypes. Its value is greatest when reporter, protein, and long-term proliferation assays are combined rather than interpreted from viability data alone.
-
HyperPFU™ high-fidelity DNA polymerase Guide
2026-08-27
HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is suitable for blunt-ended cloning and sequencing workflows, but not for protocols that require 3′-A overhangs or preformed sticky ends.
-
HOBt for Peptide and Medicinal Chemistry Workflows
2026-08-26
HOBt supports high-fidelity amide bond formation when stereochemical control and mild activation are important. This practical guide connects peptide synthesis with the modular medicinal-chemistry workflow used to develop indazole- and indole-based glucagon receptor antagonists.
-
Mifepristone (RU486): Receptor-Aware Assays
2026-08-26
Mifepristone (RU486) is more than a progesterone receptor antagonist: it is a valuable perturbation tool for dissecting hormone-dependent phenotypes. This guide connects oncology and reproductive assays with tissue-specific nuclear receptor biology and practical controls.
-
BAF53a, EMT, and Glioma Prognosis
2026-08-25
Meng et al. identify BAF53a as a prognostic biomarker associated with overall and progression-free survival in glioma and show that altering BAF53a levels changes glioma-cell proliferation, motility, invasion, and EMT-associated marker expression. The study provides a useful mechanistic hypothesis linking a chromatin-remodeling complex subunit with aggressive glioma behavior, while its retrospective cohort and single-cell-line experiments indicate that independent validation is still required.
-
Anti Reverse Cap Analog for Reliable Cell Assays
2026-08-25
A scenario-based guide to using Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G (SKU B8175) to improve synthetic mRNA translation workflows that support cell viability, proliferation, and cytotoxicity studies. It connects cap chemistry, IVT optimization, assay controls, and practical product-selection criteria with product data and peer-reviewed evidence.
-
Puromycin aminonucleoside Podocyte Workflows
2026-08-24
Build more reproducible podocyte injury and nephrotic disease experiments with a workflow that connects reagent handling, pH-aware cell assays, renal functional endpoints, and blinded pathology. The article also converts a stage-aware strategy from a prostate cancer chemoprevention study into clearly bounded assay-design lessons without confusing mechanistic evidence across organs.
-
Praeruptorin A: Assay Workflows & Troubleshooting
2026-08-24
Build reproducible inflammation, ferroptosis, cardiomyopathy, and metastasis assays around Praeruptorin A with dose-finding, pathway-level validation, and practical troubleshooting. The workflow separates reference-backed observations from optimization recommendations so researchers can exploit this angular pyranocoumarin compound without overinterpreting multi-target biology.
-
Light-Inducible RNA Release for Regulated Gene Therapy
2026-08-23
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls mammalian translation without requiring a separate effector domain. In mouse models, LIRP enabled reversible, light-dependent regulation of therapeutic transgenes for obesity and retinal neovascular disease, highlighting a potential safety and dosing advantage for gene therapies.